1 – 9 of 9
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
Personal comorbidities and their subsequent risks for liver, gallbladder and bile duct cancers
(
- Contribution to journal › Article
-
Mark
Autoimmune diseases as comorbidities for liver, gallbladder, and biliary duct cancers in Sweden
(
- Contribution to journal › Article
-
Mark
Population-Attributable Fractions of Personal Comorbidities for Liver, Gallbladder, and Bile Duct Cancers
(
- Contribution to journal › Article
- 2022
-
Mark
Familial Risks for Liver, Gallbladder and Bile Duct Cancers and for Their Risk Factors in Sweden, a Low-Incidence Country
(
- Contribution to journal › Article
-
Mark
Circulating Tumor Cell Kinetics and Morphology from the Liquid Biopsy Predict Disease Progression in Patients with Metastatic Colorectal Cancer Following Resection
(
- Contribution to journal › Article
- 2021
-
Mark
Second primary cancers after liver, gallbladder and bile duct cancers, and these cancers as second primary cancers
(
- Contribution to journal › Article
- 2020
-
Mark
Epistatic effect of TLR3 and cGAS-STING-IKKε-TBK1-IFN signaling variants on colorectal cancer risk
(
- Contribution to journal › Article
- 2018
-
Mark
Short article : Influence of regulatory NLRC5 variants on colorectal cancer survival and 5-fluorouracil-based chemotherapy
(
- Contribution to journal › Article
-
Mark
Investigation of single and synergic effects of NLRC5 and PD-L1 variants on the risk of colorectal cancer
(
- Contribution to journal › Article